文献リスト

1）Chan JKC, Quintanilla-Martinez L, Ferry JA, et al. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008; p.285-8

2）Suzuki R. Leukemia and lymphoma of natural killer cells. J Clin Exp Hematop. 2005; 45: 51-70

3）Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007; 139: 532-44

4）Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma ? Ann Oncol. 2001; 12: 349-52

5）Suzuki R, Suzumiya J, Yamaguchi M, et al. Prognostic factors for mature natural killer (NK)-cell neoplasms: aggressive NK-cell leukemia and extranodal NK-cell lymphoma, nasal-type. Ann Oncol. 2010; 21: 1032-40

6）Suzuki R. NK/T-cell lymphomas: pathobiology, prognosis and treatment paradigm. Current Oncol Rep. 2012; 14: 395-402

7）Suzuki R, Takeuchi K, Ohshima K, et al. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol. 2008; 26: 66-72

8）Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004; 103: 216-21

9）Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood. 2005; 106: 3785-90

10）Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006; 24: 612-8

11）Li YX, Coucke PA, Li JY, et al. Primary non-Hodgkinʼs lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer. 1998; 83: 449-56

12）Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004; 100: 366-75

13）Ng SB, Lai KW, Murugaya S, et al. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol. 2004; 17: 1097-107

14）Cuadra-Garcia I, Proulx GM, Wu CL, et al. Sinonasal lymphoma: a clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol. 1999; 23: 1356-69

15）Aviles A, Diaz NR, Neri N, et al. Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol. 2000; 22: 215-20

16）Barrionuevo C, Zaharia M, Martinez MT, et al. Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru. Appl Immunohistochem Mol Morphol. 2007; 15: 38-44

17）Gualco G, Domeny-Duarte P, Chioato L, et al. Clinicopathologic and molecular features of 122 Brazilian cases of nodal and extranodal NK/T-cell lymphoma, nasal type, with EBV subtyping analysis. Am J Surg Pathol. 2011; 35: 1195-203

18）Chauchet A, Michallet AS, Berger F, et al. Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. J Hematol Oncol. 2012; 5: 27

19）Pongpruttipan T, Sukpanichnant S, Assanasen T, et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: A Comprehensive Clinicopathologic and Phenotypic Study. Am J Surg Pathol. 2012; 36: 481-99

20）Ahn HK, Suh C, Chuang SS, et al. Extranodal natural killer/T cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. Ann Oncol. 2012; 23: 2703-7

21）Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal NK/T-cell lymphoma: a study of 136 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2009; 113: 3931-7

22）Suzuki R, Suzumiya J, Oshimi K. Differences between nasal and extra-nasal NK/T-cell lymphoma. Blood. 2009; 113: 6260-1

23）Egashira M, Kawamata N, Sugimoto K, et al. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 1999; 93: 599-606

24）Cheung MMC, Chan JKC, Lau WH, et al. Primary non-Hodgkinʼs lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998; 16: 70-7

25）Kim GE, Koom WS, Yang WI, et al. Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis. Head Neck. 2004; 26: 584-93

26）Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006; 24: 181-9

27）Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009; 27: 5594-600

28）Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma Study. J Clin Oncol. 2009; 27: 6027-32

29）Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: The NK-cell Tumor Study Group (NKTSG) study. J Clin Oncol. 2011; 29: 4410-6

30）Suzuki R. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. Int J Hematol. 2010; 92: 697-701

31）Takahashi H, Sakai R, Hattori Y, et al. Successful disease control with l-asparaginase monotherapy for aggressive natural killer cell leukemia with severe hepatic failure. Leuk Lymphoma. 2013; 54: 662-4

32）Ishida F, Ko YH, Kim WS, et al. Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci. 2012; 103: 1079-83

33）Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012; 120: 2973-80

34）Suzuki R, Kwong Y, Maeda Y, et al. Long-term follow-up of the phase II study of SMILE chemotherapy for patients with newly disgnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: the NK-cell Tumor Study Group study. Hematol Oncol. 2013; 31 (Supple. S1): 175. [Abstract #235]

35）Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase II study. Blood. 2011; 117: 1834-9

36）Jaccard A, Suerez F, Delmer A, et al. A prospective phase II trial of an L-asparaginase containing regimen in extranodal NK/T-cell lymphoma. Hematol Oncol. 2013; 31 (Supple. S1): 129. [Abstract #099]

37）Suzuki R, Suzumiya J, Nakamura S, et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant. 2006; 37: 425-31

38）Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005; 130: 561-7

39）Au WY, Lie AK, Liang R, et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol. 2003; 14: 1673-6

40）Kim HJ, Bang SM, Lee J, et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant. 2006; 37: 819-24

41）Lee J, Au WY, Park MJ, et al. Autologous hematopoietic stem cell transplantation in extranodal NK/T-cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008; 14: 1356-64

42）Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006; 24: 612-8

43）Suzuki R. Pathogenesis and treatment of extranodal NK/T cell lymphoma. Semin Hematol. 2014 (in press)

44）Suzuki R, Kako S, Hyo R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for extranodal NK/T-cell lymphoma, nasal-type: Analysis of The Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group. Blood. 2011; 118: 503a. [Abstract #503]

45）Kimura H, Ito Y, Suzuki R, et al. Measuring Epstein-Barr virus (EBV) load: its significance and application in each EBV-associated disease. Rev Med Virol. 2008; 18: 305-19

46）Chan KCA, Zhang J, Chan ATC, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 2003; 63: 2028-32

47）Lei KIK, Chan LYS, Chan W-Y, et al. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res. 2002; 8: 29-34

48）Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004; 104: 243-9

49）Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011; 118: 6018-22

50）Ito Y, Kimura H, Maeda Y, et al. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type. Clin Cancer Res. 2012; 18: 4183-90

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp